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Frequent mutation of hypoxia-related
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hypertension of the newborn
Mingbang Wang1*† , Deyi Zhuang2†, Mei Mei3†, Haiyan Ma4, Zixiu Li5, Fusheng He6, Guoqiang Cheng7,8,
Guang Lin4* and Wenhao Zhou1*
Abstract
Aims: Persistent pulmonary hypertension of the newborn (PPHN) is characterized by sustained high levels of pulmonary
vascular resistance after birth with etiology unclear; Arterial blood oxygen saturation of Tibetan newborns at high
latitudes is higher than that of Han newborns at low latitudes, suggesting that genetic adaptation may allow sufficient
oxygen to confer Tibetan populations with resistance to pulmonary hypertension; We have previously identified genetic
factors related to PPHN through candidate gene sequencing; In this study, we first performed whole exome sequencing
in PPHN patients to screen for genetic-related factors.
Methods and results: In this two-phase genetic study, we first sequenced the whole exome of 20 Tibetan PPHN
patients and compared it with the published genome sequences of 50 healthy high-altitude Tibetanshypoxia-related
genes, a total of 166 PPHN-related variants were found, of which 49% were from 43 hypoxia-related genes; considering
many studies have shown that the differences in the genetic background between Tibet and Han are characterized by
hypoxia-related genetic polymorphisms, so it is necessary to further verify whether the association between hypoxia-
related variants and PPHN is independent of high-altitude life. During the validation phase, 237 hypoxia-related genes
were sequenced in another 80 Han PPHN patients living in low altitude areas, including genes at the discovery stage
and known hypoxia tolerance, of which 413 variants from 127 of these genes were shown to be significantly associated
with PPHN.hypoxia-related genes.
Conclusions: Our results indicates that the association of hypoxia-related genes with PPHN does not depend on high-
altitude life, at the same time, 21 rare mutations associated with PPHN were also found, including three rare variants of
the tubulin tyrosine ligase-like family member 3 gene (TTLL3:p.E317K, TTLL3:p.P777S) and the integrin subunit alpha M
gene (ITGAM:p.E1071D). These novel findings provide important information on the genetic basis of PPHN.
Keywords: Persistent pulmonary hypertension of the newborn, Whole exome sequencing, Target region sequencing,
Hypoxia tolerance
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Introduction
Persistent pulmonary hypertension of the newborn (PPHN)
affects 1.9 per thousand live births and is one of the import-
ant factors leading to neonatal mortality [1], the main
feature of patients with PPHN is that pulmonary vascular
resistance cannot be rapidly reduced to increase pulmonary
blood flow and oxygen levels and to adapt to the postnatal
environment [2]. Although PPHN can be rapidly diagnosed
and treated with vasodilators and life support, the mortality
rate remains high, at 8–10%. In surviving patients, PPHN
can cause neurological damage, cerebral palsy, deafness,
blindness, and other complications [3, 4]. Sustained hypoxia
resulting from PPHN has been associated with pulmonary
vascular dysfunction, alveolar capillary dysplasia, severe lung
dysplasia, and progressive lung injury [5]. Epidemiological
data also support the association between PPHN and the
development of lung disease [5, 6]. Inhaled nitric oxide, a
selective pulmonary vasodilator, is widely used in PPHN
therapy; however, 30–40% of treated patients, particularly
those with pulmonary parenchymal lesions and pulmonary
hypoplasia, fail to achieve sustained improvement in oxy-
genation [7]. These findings suggest that there may be a
genetic basis for the disease in some PPHN patients.
Recent studies have shown that genetic factors play an
important role in the pathogenesis of pulmonary arterial
hypertension (PAH) [8]. However, unlike PAH, PPHN is
rarely familial and there has been little research on potential
genetic associations [2]. We previously used target region
sequencing (TRS) of genes associated with vascular activity
in PPHN patients, and we found a significant association
between the disease and a variant of the EDN1 endothelin
1-coding gene [9], recently, we screened clinically relevant
mutations in children with PPHN patients through a target
panel containing more than 2700 rare disease-related genes
[10]. Niermeyer et al. found that the arterial oxygen satur-
ation at birth and in the first 4 months after birth in Tibet
(3658m above sea level) was higher than that in Han new-
borns at plain, suggesting that genetic adaptation may
allow sufficient oxygen to confer resistance to pulmon-
ary hypertension [11]; at the same time, recent
genome-wide studies have found that genetic basis of
Tibetan population adapts to high-altitude chronic hyp-
oxia, hypoxia-inducible factor pathway gene polymor-
phisms are significantly different among Tibetans and
Han population [12].
In the present study, we sought to extend this study by
screening for gene variants associated with PPHN in the
high altitudes Tibetan population, which exhibits high
adaptability to hypoxia and confers resistance to pul-
monary hypertension. We first performed whole exome
sequencing (WES) of 20 Tibetan PPHN patients and
compared the results with a published dataset of 50
healthy Tibetan individuals to find PPHN-related single
nucleotide polymorphisms (SNPs). We then validated in
80 patients from plain PPHN populations to see if the
PPHN-related SNPs were independent of high altitudes.
Materials and methods
Patients
The high altitudes PPHN patients were recruited from
Lhasa People’s Hospital, and the plain PPHN patients
were recruited from Children’s Hospital of Fudan Uni-
versity. PPHN was diagnosed by clinical and echocardio-
graphic data, as detailed in our previous study [9].
Informed consent was obtained from a parent, and the
study was approved by the ethics committee of the Chil-
dren’s Hospital of Fudan University (No. 2015–169).
Whole exome and targeted region sequencing
Genomic DNA was extracted from patient peripheral
blood (1–2 ml) samples using a Magbind Blood DNA
Kit (CW Biotech, Beijing, China) according to the manu-
facturer’s instructions and was stored at − 20 °C. WES
and TRS were performed as previously described [9, 13].
In brief, whole exomes were captured using SeqCap EZ
Exome (44M) arrays (Roche, Basel, Switzerland). The
targeted region was captured using a SeqCap Target En-
richment Kit (Roche) and sequenced using an Illumina
HiSeq 2500 System (Illumina, San Diego, CA, USA) at
BGI-Shenzhen (BGI, Shenzhen, China).
Bioinformatics and statistical analysis
Discovery stage
For the case–control differential analysis, the raw WES
datasets from 20 Tibetan PPHN patients were the cases
and published WES datasets from 50 healthy Tibetan in-
dividuals [14] were the controls. First, all raw sequencing
data were pre-processed using a customized bioinfor-
matics pipeline as described previously [15], and clean
reads were generated by removing adapters and filtering
out low-quality reads with Trimmomatic [16]. Clean
reads were then aligned to the human reference genome
(Hg19) using the BWA-MEM algorithm [17] and further
visualized using the SplicingViewer software [18], vari-
ants were called using GATK [19], and the variants were
functionally annotated using ANNOVAR [20]. We then
filtered out variants at depths of <20 in the PPHN sam-
ples and at depths of <10 in the controls, and Fisher’s
exact test was used to determine the difference between
PPHN and controls. P < 0.001 was considered significant.
Genes with PPHN-associated variants were further
enriched according to the KEGG pathway database (ver-
sion 76 [21]). P values were determined using Fisher’s
exact test, and Q values were determined by false-
discovery rate correction of the P values. Q < 0.05 was
considered significant.
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Validation stage
To validate the identified PPHN-associated variants in
plain population, an additional 80 PPHN patients were
sequenced. Variants at depths <20 were filtered out and
published 800 healthy controls WES dataset [22] were
used as controls for differences analysis using Fisher’s
exact test (P value no more than 0.05 were considered
significant). The association between gene variants and
PPHN was predicted using Phenolyzer [23]. Non-
synonymous variants with allelic frequencies of ≤0.01 in
the Exome Aggregation Consortium (ExAC) database
were considered potential disease-causing variants.
Results
A flowchart of the study design is shown in Fig. 1. Clinical
information on the study participants is given in Add-
itional file 1: Table S1. In the discovery stage, the average
sequencing depth for the 20 Tibetan PPHN patients and
50 Tibetan controls were 40× and 20×, respectively. After
strictly filtering out variants with no or low-depth cover-
age (i.e., < 20 and < 10 for PPHN patients and controls,
respectively), a total of 2023 variants were identified (Add-
itional file 1: Table S2) and subjected to case–control dif-
ferential analysis. Using Fisher’s exact test for single-locus
association analysis, a total of 166 significant differences
were identified (P < 0.001, Additional file 1: Table S3).
In a KEGG pathway analysis, we identified eight path-
ways enriched in genes with PPHN-associated variants
(Q < 0.05, Table 1). These were Renal cell carcinoma, Sal-
monella infection, Pathways in cancer, Graft-versus-host
disease, HIF-1 (hypoxia-inducible factor 1) signaling path-
way, Bladder cancer, Regulation of actin cytoskeleton, and
Gap junction. HIF-1 is a transcription factor that controls
the expression of numerous hypoxia-related genes and
plays a crucial role in cancer biology [24]. We found that
three of the HIF-1 signaling pathway-associated genes;
namely, EGF, EP300, and IL6, were also present in the
other seven pathways enriched in PPHN-associated vari-
ants (Additional file 1: Table S4). Therefore, we turned our
focus to genes in the HIF-1 signaling pathway. Interestingly,
49% (80/166) of the PPHN-associated variants were genes
regulated by hypoxia or related to hypoxia tolerance
Fig. 1 Flowchart of the study design. HIF-1 = hypoxia-inducible factor-1; PPHN = persistent pulmonary hypertension of the newborn; SNVs = single
nucleotide variants; WES = whole exome sequencing
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(Additional file 1: Table S5); we refer to these as hypoxia-
related genes.
To verify whether the correlation between hypoxia-
related associated genes and PPHN is independent of
high altitude, we first conducted a systematic literature
search and identified 246 hypoxia-related genes (Add-
itional file 1: Table S5), and then designed a capture chip
that captures the exon regions of 246 hypoxia-related
genes, finally, the targeted region was sequenced in 80
plain PPHN patients with an average depth of 100x. As
in the discovery stage, we use strict filtering standards to
remove variants with no or low-depth coverage in the
controls, and identified a total of 413 variants signifi-
cantly associated with PPHN (P < 0.05, Additional file 1:
Table S6) in 127 of the 246 hypoxia-related genes. Of
these 413, only 5% (21) were population-specific variants
(P < 0.05, Additional file 1: Table S7) and were not con-
sidered rare (minor allele frequency [MAF] > 0.05 in the
ExAC database). Most of these variants (20/21) were lo-
cated in the intronic or exonic regions and did not result
in amino acid changes. One missense variant was associ-
ated with the FANCA (Fanconi anemia complementation
group A) gene.
Eighteen of the PPHN-associated variants consisted of
non-synonymous mutations in 14 genes; ANP32D,
C12orf54, DR1, DUOXA1, FANCA, ITGAM, MBL2,
MDH1B, PFKM, PLAU, PTX3, SIPA1L2, TMEM206, and
TTLL3 (Table 2). Most of these variants (15/18) were
not rare (MAF > 0.01) in ExAC. The three rare (MAF <
0.01) variants were two missense mutations in TTLL3
Table 1 Pathways enriched in PPHN-Associated gene variants identified in the tibetan population
Pathway name Pathway ID PPHN genes (114) All genes (17251) P value Q value
Renal cell carcinoma ko05211 7 101 4.71E-06 0.001
Salmonella infection ko05132 10 317 4.79E-05 0.005
Pathways in cancer ko05200 14 644 8.85E-05 0.006
Graft-versus-host disease ko05332 5 74 0.0001293 0.006
HIF-1 signaling pathway ko04066 7 185 0.0002281 0.009
Bladder cancer ko05219 4 61 0.0007062 0.023
Regulation of actin cytoskeleton ko04810 11 588 0.0017709 0.050
Gap junction ko04540 5 135 0.0020232 0.050
Definition of abbreviations: HIF-1 Hypoxia-inducible factor-1, PPHN Persistent pulmonary hypertension of the newborn
Table 2 PPHN-Associated missense variants identified in the han population
Chr Pos Ref Alt Variants Gene PPHN (MAF) Ctrl (MAF) P value OR MAFa
chr12 48,866,585 A C p.L46F ANP32D 0.604 0.687 0.0487 0.69 0.187
chr12 48,888,594 C T p.P86S C12orf54 0.188 0.12 0.0265 1.70 0.372
chr1 93,826,178 A T p.E171D DR1 0.052 0.016 0.0121 3.31 0.092
chr15 45,409,732 C G p.R433P DUOXA1 0.071 0.033 0.0365 2.28 0.083
chr16 89,857,935 G A p.A412V FANCA 0.156 0.29 0.0005 0.45 0.065
chr16 89,805,914 T C p.T1328A FANCA 0.156 0.274 0.0017 0.49 0.031
chr16 89,839,766 G C p.P643A FANCA 0.182 0.297 0.0032 0.53 0.025
chr16 89,836,323 C T p.G809D FANCA 0.968 0.99 0.0443 0.30 0.467
chr16 31,341,863 G C p.E477D ITGAM 0.026 0.005 0.027 5.29 0.001
chr10 54,531,235 C T p.G54D MBL2 0.13 0.209 0.0262 0.57 0.139
chr2 207,603,221 T C p.T515A MDH1B 0.052 0.021 0.0475 2.52 0.087
chr12 48,501,161 A T p.H2L PFKM 0.532 0.621 0.0473 0.70 0.266
chr10 75,673,101 T C p.L105P PLAU 0.558 0.682 0.0038 0.59 0.755
chr3 157,155,314 C A p.A48D PTX3 0.857 0.775 0.0234 1.74 0.625
chr1 232,539,219 C T p.G695S SIPA1L2 0.442 0.544 0.0218 0.66 0.065
chr1 212,587,320 T C p.N47D TMEM206 0.162 0.088 0.0076 2.02 0.035
chr3 9,876,568 C T p.P777S TTLL3 0.026 0.005 0.027 5.29 0.001
chr3 9,860,595 G A p.E317K TTLL3 0.006 0.038 0.0463 0.17 0.001
aMinor allele frequency (MAF) according to the Exome Aggregation Consortium database. Definition of abbreviations: Alt Alteration, Chr Chromosome, Ctrl Control,
Pos Position, OR Odds ratio, PPHN Persistent pulmonary hypertension of the newborn, Ref Reference
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(tubulin tyrosine ligase-like 3), p.E317K and p.P777S,
and one missense mutation in ITGAM (integrin subunit
alpha M), p.E1071D. Both TTLL3 and ITGAM were pre-
dicted to be associated with the PPHN phenotype using
Phenolyzer (P = 0.002589 and P = 0.03325, respectively).
Discussion
In this two-stage study, we first compared WES data from
20 Tibetan PPHN patients and 50 healthy Tibetan con-
trols living at high altitudes and identified 166 PPHN-
associated variants, 49% of which were derived from 43
hypoxia-related genes; considering many studies have
shown that the differences in the genetic background be-
tween Tibet and Han are characterized by hypoxia-related
genetic polymorphisms [12]; to further verify whether the
association of hypoxia-associated variants with PPHN is
independent of high altitude life, we performed a targeted
validation study of hypoxia-related genes in an additional
80 Han PPHN patients living at low altitudes. Finally, we
discovered 413 PPHN-associated variants from 127
hypoxia-related genes in Han population.
Significant changes in blood coagulation at high alti-
tudes may predispose individuals to pulmonary hyperten-
sion [25, 26]. Negi et al. [27] conducted a cross-sectional
survey of permanent inhabitants in the Spiti Valley at an
altitude of 3000 to 4200m, although no significant correl-
ation was found between altitude and pulmonary hyper-
tension. However, it is still found that the prevalence rate
is increasing with the increase of altitude; the data pub-
lished to date have not been identified in plateau popula-
tions as genetic susceptibility to individual pulmonary
hypertension [28, 29]. Our results indicates that the asso-
ciation of hypoxia-related genes with PPHN does not de-
pend on high-altitude life, at the same time, some rare
mutations associated with PPHN were also found.
Two rare missense mutations identified in TTLL3
(p.E317K and p.P777S) were associated with PPHN. TTLL3
catalyzes the ATP-dependent restoration of tyrosine to the
C-terminus of α-tubulin, which polymerizes into microtu-
bules [30, 31]. Microtubule proliferation has been found in
the right ventricular myocytes of rats with monocrotaline-
induced pulmonary hypertension, accompanied by upregu-
lated expression of α- and β-tubulin [32]. The detyrosina-
tion/tyrosination cycle of tubulin is important for
regulating the mechanical stabilization of long-lived micro-
tubules in cells, and abnormalities in this cycle are involved
in the development of hypertension [33]. A recent study
found that TTLL3 can also ligate various unnatural amino
acids to the C-terminus of tubulin [34]. The crystal struc-
ture of TTLL3 has recently been solved and suggests that
TTLL3 can ligate glycine and glutamate to the tubulin C-
terminus, a process crucial for the biogenesis and stability
of microtubules in cilia, flagella, spindles, neuronal pro-
cesses, and platelets [35, 36]. Glutamylation, the most
prevalent post-translational modification of tubulin, stabi-
lizes microtubules and regulates the recruitment and activ-
ity of microtubule-interacting proteins [37]. Valenstein
et al. found that glutamylation was a major regulator of her-
editary spastic paraplegia [38]. Consistent with the potential
importance of microtubule-associated proteins in PPHN,
we found significant enrichment of genes associated with
regulation of the actin cytoskeleton among the 166 PPHN-
associated variants identified in the Tibetan population.
These included TTLL3, EGF, GOLGA1, KRAS, IQGAP1,
LRRFIP2, RB1CC1, TEX14, GCOM1, ARPC4-TTLL3, and
MYZAP. Interestingly, Fediuk et al. found that the eicosa-
noid thromboxane can induce actin polymerization in hyp-
oxic neonatal pulmonary arterial myocytes [39, 40].
Rare missense mutation identified in in ITGAM
(p.E1071D) was associated with PPHN, ITGAM encodes
the integrin alpha M chain, also known as Mac-1, CD11b/
CD18, or CR3A. Integrins play important roles in cell–cell
adhesion by mediating transmembrane connections to the
cytoskeleton and activating intracellular signaling path-
ways. A previous study showed that integrins are differen-
tially regulated in pulmonary artery smooth muscle cells
during pulmonary hypertension [41]. In addition, pulmon-
ary artery endothelial cells from patients with idiopathic
pulmonary hypertension show decreased adhesion to lam-
inin, and loss of interaction between α3 integrins and the
tumor promoter APC (adenomatous poliposis coli) pro-
motes endothelial apoptosis in mice and humans [42]. Fur-
thermore, a recent study showed that induced pluripotent
stem cell-derived endothelial cells from a patient with
familial PAH showed reduced adhesion compared with
control cells [43]. The missense mutation identified in the
present study, p.E1071D, lies in the C-terminal domain of
ITGAM, which may be responsible for recognizing short
peptide motifs [44] that are involved in integrin–extracel-
lular matrix interactions. This suggests a potential mechan-
ism by which aberrant behavior of the ITGAM variant
may contribute to PPHN.
Nevertheless, it is unclear how this integrin may be in-
volved in PAH or PPHN or whether the ITGAM muta-
tion is protective or a risk factor. Jiang et al. found that
platelet-mediated mesenchymal stem cell homing to the
lung can reduce monocrotaline-induced rat pulmonary
hypertension [45]. A recent study showed that ITGAM
can regulate thrombosis via interaction with platelet
GPIb [46], suggesting that it may play a protective func-
tion against thrombosis. However, upregulation of
integrins may also be associated with the onset of
PPHN, as previous studies have shown that integrins
αvβ6 and αvβ8 are upregulated in bronchial epithelial
cells from patients with systemic sclerosis, a disease
often associated with PAH [47]. Welschoff et al. found
that the tripeptide Arg-Gly-Asp, which inhibits the
adhesion of several integrins, can induce relaxation of
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pulmonary arteries and reduce pulmonary arterial pres-
sure [48].
PPHN is not a single disease, but a clinical syndrome
caused by multiple factors, that may present with different
clinical conditions requiring different treatments and with
variable outcomes. The PPHN related genetic variants we
described could improve the understanding of the patho-
genesis of PPHN and, consequently, increase the spectrum
of available treatments by targeting hypoxia related gene
pathways [49, 50] . Finally our paper may also suggest the
feasibility of whole-genome sequencing for the screening
of clinically relevant mutations, associated with PPHN.
This study has some innovations. To the best of our
knowledge, we have performed exome screening for the
first time in PPHN patients; we found that hypoxia-related
genes are associated with PPHN and are not dependent
on high altitudes. It provides a genetic basis for the patho-
genesis of PPHN and also provides a target for our PPHN
genetic screening in newborns. There are some limitations
to our study. The published Tibetan WES datasets used as
controls were of low coverage, and the rigorous filtering
may have eliminated Tibetan-specific variants associated
with PPHN. Although we have identified three rare mis-
sense variants associated with PPHN, further functional
studies will be necessary to understand how they contrib-
ute to the pathogenesis of PPHN.
Conclusions
We conducted a two-stage genetic study of 100 PPHN
patients and identified several hypoxia-associated gene
variants that may be associated with PPHN, and the as-
sociation of hypoxia-associated gene mutations with
PPHN does not depend on high altitude life.
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